HOME Research Insight Product Launches was the Most-preferred Strategy Followed by Key Players in the Anatomic Pathology Market



Product Launches was the Most-preferred Strategy Followed by Key Players in the Anatomic Pathology Market


The growth of the anatomic pathology market can be attributed to the increasing prevalence of chronic diseases, growing aging population, and increasing healthcare expenditure.

Major players in the anatomic pathology market include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Sakura Finetechnical Co., Ltd. (Japan), Quest Diagnostics Incorporated (U.S.), Laboratory Corporation of America Holdings (U.S.), and NeoGenomics Laboratories, Inc. (U.S.).

F. Hoffmann-La Roche AG (Switzerland) accounted for the largest share of 27.5% of the anatomic pathology products market in 2015. The company focuses on product launches in order to strengthen its position in the anatomic pathology market. In March 2016, the company launched its VENTANA PD-L1 (SP142) Assay to provide PD-L1 status in patients with metastatic urothelial cancer (mUC); this product launch helped the company strengthen its anatomic pathology product portfolio.

Danaher Corporation (U.S.) accounted for the second-largest share 22% of the anatomic pathology products market in 2015. It focuses on collaborations and agreements to strengthen its position in the market. In March 2014, Leica Biosystems entered into an agreement with GNYHA Services (U.S), an acute care group purchasing and supply chain management organization. According to the terms of this agreement, Leica Biosystems offered its anatomical pathology products and innovations to GYNHA Services members to help them increase efficiencies and diagnostic confidence.

Thermo Fisher Scientific, Inc (U.S.) accounted for the third-largest share of 12.0% of the anatomic pathology market in 2015. The company focuses on expansions and acquisitions to maintain its leading position in the anatomic pathology market. In September 2015, the company acquired Alfa Aesar (U.S.), a leader in the manufacturing of research chemicals that are used in various applications ranging from research to production. This acquisition helped the company to strengthen its existing chemicals portfolio.

Agilent Technologies (U.S.) accounted for the fourth-largest share of 11.4% of the anatomic pathology market in 2015. The company mainly focuses on product launches and agreements in order to strengthen its position in the market. In April 2016, Dako, (a subsidiary of Agilent Technologies) launched a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells.

Based on the analysis of strategic developments undertaken by market players between 2014 and 2017, the key strategy followed by most companies in the market is product launches. Some of the leading players that adopted this strategy include F. Hoffmann-La Roche AG (Switzerland), Thermo Fisher Scientific (U.S.), Danaher Corporation (U.S.), BioGenex Laboratories (U.S.), and Bio SB (U.S.).

Related Reports:

Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtome), Consumables (Reagent & Antibodies), Histopathology, Cytopathology), Application (Disease Diagnosis, Drug Discovery & Development) - Forecasts to 2021

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports